CHINA MESALAZINE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2022 - 2030)

Mesalazine is used to treat ulcerative colitis and Crohn's disease and other types of inflammatory bowel disease. Mesalazine is also known as mesalamine or 5-aminosalicylic acid (5-ASA). It belongs to a group of medicines called aminosalicylates that help to reduce redness and swelling (inflammation). It suppresses the production of chemical messengers (prostaglandins) that cause inflammation (swelling) in the intestines. This reduces ulceration, bleeding, and stomach pain, and prevents future flare-ups of the disease. Mesalazine is a bowel-specific aminosalicylate drug that is metabolized in the gut after oral administration and has predominant actions, flatulence, headache, vomiting, diarrhea, nausea, abdominal pain, rash, and dyspepsia are the common side effects of mesalazine drug. Ulcerative colitis and Crohn’s disease are chronic relapsing conditions generally characterized by repetitive cycles of active and quiescent disease. Intestinal inflammation can result in bleeding and anemia, perforation with abscess or fistula formation, or subsequent fibrosis with intestinal obstruction. Mesalazine is only available on prescription and comes as tablets, granules, rectal foam, suppositories, and enemas.   

Market Dynamics

Increasing adoption of inorganic strategies such as agreement by key market players is expected to drive China mesalazine market growth over the forecast period. For instance, in December 2020, Takeda Pharmaceutical Company Limited, a pharmaceutical company, announced that it had agreed with Hasten Biopharmaceutic Co., Ltd., a pharmaceutical company, to divest a portfolio of non-core prescription pharmaceutical products sold in China. Takeda Pharmaceutical Company Limited will receive US$ 322 million, subject to customary legal and regulatory closing conditions.

Key features of the study:

• This report provides an in-depth analysis of China mesalazine market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in China mesalazine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Zhejiang Hengkang Pharmaceutical Co. Ltd., Jiangsu Jubang Pharmaceutical Co., Ltd., ALP Pharm Beijing Co., Ltd., Shanghai Pharmaceuticals Holding Co Ltd., Heilongjiang Tianhong Pharmaceutical Co., Ltd., AbbVie Inc., F. Hoffmann-La Roche AG, Takeda Pharmaceuticals Company Limited, GSK Plc., Tillotts Pharma AG, Novartis AG, Salix Pharmaceuticals, FERRING B.V., Viatris Inc., and Dr. Falk Pharma GmbH
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• China mesalazine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing China mesalazine market

Detailed Segmentation:

• China Mesalazine Market, By Route of Administration:
  • Oral
  • Rectal
• China Mesalazine Market, By Application:
  • Ulcerative Colitis
  • Crohn's Disease
  • Inflammatory Bowel Disease
• China Mesalazine Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Company Profiles
  • Zhejiang Hengkang Pharmaceutical Co. Ltd.*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Jiangsu Jubang Pharmaceutical Co., Ltd.
  • ALP Pharm Beijing Co., Ltd.
  • Shanghai Pharmaceuticals Holding Co Ltd.
  • Heilongjiang Tianhong Pharmaceutical Co., Ltd.
  • AbbVie Inc.
  • Hoffmann-La Roche AG
  • Takeda Pharmaceuticals Company Limited
  • GSK Plc.
  • Tillotts Pharma AG
  • Novartis AG
  • Salix Pharmaceuticals
  • FERRING B.V.
  • Viatris Inc.
  • Falk Pharma GmbH

 “*” marked represents similar segmentation in other categories in the respective section.